Eidos Therapeutics, a subsidiary of BridgeBio Pharma, is developing AG10 as a targeted therapeutic for transthyretin amyloidosis. The company’s singular mission is to improve and prolong the lives of patients suffering from this disease. Launched in 2016 after years of research supported by Stanford’s SPARK program, Eidos is led by a team of veteran biotechnology executives. Together with patients and physicians, the company aims to bring a safe, effective treatment to market as quickly as possible.
Looking for a particular Eidos Therapeutics employee's phone or email?
The Eidos Therapeutics annual revenue was $12.7 million in 2026.
Uma Sinha is the Chief Scientific Officer of Eidos Therapeutics.
26 people are employed at Eidos Therapeutics.
Eidos Therapeutics is based in San Francisco, California.
The NAICS codes for Eidos Therapeutics are [54171, 541712, 541711, 541, 54, 5417].
The SIC codes for Eidos Therapeutics are [87, 873].